BR0308280A - Oxo-azabicyclic compounds - Google Patents
Oxo-azabicyclic compoundsInfo
- Publication number
- BR0308280A BR0308280A BR0308280-6A BR0308280A BR0308280A BR 0308280 A BR0308280 A BR 0308280A BR 0308280 A BR0308280 A BR 0308280A BR 0308280 A BR0308280 A BR 0308280A
- Authority
- BR
- Brazil
- Prior art keywords
- group
- integer
- formula
- description
- oxo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
"COMPOSTOS OXO-AZABICìCLICOS". A presente invenção refere-se a um composto selecionado dos de fórmula (I) em que X~ 1~, X~ 2~ e X~ 3~ representam N ou -CR~ 3~ em que R3 é como descrito na descrição, G1 representa um grupo selecionado dos de fórmulas (i/a) e (i/b) em que R~ 4~, R~ 5~ e R~ 6~ são como definidos na descrição,>sym> G2 representa um grupo selecionado de ligação tripla carbono-carbono, -CH=C=CH-, C=O, C=S, S(O)~ n~ em que n1 representa um número inteiro desde O até 2 inclusive ou um grupo de fórmula (i/c) em que Y~ 1~ representa O, S, -NH ou -Nalquila, e Y~ 2~ representa O, S, -NH ou -Nalquila, n é um número inteiro desde 0 até 6 inclusive e m é um número inteiro desde 0 até 7 inclusive, Z, representa -CR~ 9~R~ 10~, em que R~ 9~ e R~10~ são como definidos na descrição, A representa um sistema em anel, R~ 1~ representa um grupo selecionado de H, alquila, alcenila, alcinila, opcionalmente substituídas e o grupo de fórmula (i/d) em que p, Z~ 2~, B, q e G~ 3~ são como definidos na descrição e opcionalmente os seus isómeros ópticos, N-óxidos e os seus sais de adição com um ácido ou base farmaceuticamente aceitáveis e produtos farmacêuticos contendo esse composto são úteis como inibidores específicos de metaloprotease de matriz de tipo 13."OXO-AZABICIC COMPOUNDS". The present invention relates to a compound selected from those of formula (I) wherein X1, X2 and X3 represent N or -CR3 wherein R3 is as described in the description, G1. represents a group selected from those of formulas (i / a) and (i / b) wherein R 4 ~, R 5 & R 6 are as defined in the description,> sym> G 2 represents a selected linking group triple carbon-carbon, -CH = C = CH-, C = O, C = S, S (O) ~ n ~ where n1 represents an integer from 0 to 2 inclusive or a group of formula (i / c) where Y ~ 1 ~ represents O, S, -NH or -Nalkyl, and Y ~ 2 ~ represents O, S, -NH or -Nalkyl, n is an integer from 0 to 6 and n is an integer from 0 up to and including 7, Z represents -CR ~ 9 ~ R ~ 10 ~, wherein R ~ 9 ~ and R ~ 10 ~ are as defined in the description, A represents a ring system, R ~ 1 ~ represents a group selected from Optionally substituted H, alkyl, alkenyl, alkynyl and the group of formula (i / d) wherein p, Z ~ 2 ~, B, and G ~ 3 ~ are as defined in d and optionally their optical isomers, N-oxides and their addition salts with a pharmaceutically acceptable acid or base and pharmaceuticals containing such compound are useful as type 13 matrix metalloprotease specific inhibitors.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2002/003240 WO2003076416A1 (en) | 2002-03-08 | 2002-03-08 | Oxo azabicyclic compounds |
| PCT/EP2003/002277 WO2003076417A2 (en) | 2002-03-08 | 2003-03-06 | Oxo-azabicyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0308280A true BR0308280A (en) | 2004-12-28 |
Family
ID=27798761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0308280-6A BR0308280A (en) | 2002-03-08 | 2003-03-06 | Oxo-azabicyclic compounds |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1492775A2 (en) |
| JP (1) | JP2005526070A (en) |
| KR (1) | KR20040095270A (en) |
| CN (1) | CN1738806A (en) |
| AP (1) | AP2004003125A0 (en) |
| AR (1) | AR039562A1 (en) |
| AU (2) | AU2002249275A1 (en) |
| BR (1) | BR0308280A (en) |
| CA (1) | CA2478706A1 (en) |
| CO (1) | CO5601020A2 (en) |
| EA (1) | EA200401053A1 (en) |
| EC (1) | ECSP045278A (en) |
| IL (1) | IL163818A0 (en) |
| IS (1) | IS7414A (en) |
| MA (1) | MA27183A1 (en) |
| MX (1) | MXPA04008681A (en) |
| NO (1) | NO20044041L (en) |
| OA (1) | OA12782A (en) |
| PA (1) | PA8568501A1 (en) |
| PE (1) | PE20031018A1 (en) |
| PL (1) | PL372622A1 (en) |
| SV (1) | SV2003001495A (en) |
| TN (1) | TNSN04169A1 (en) |
| UY (1) | UY27700A1 (en) |
| WO (2) | WO2003076416A1 (en) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8539501A1 (en) | 2001-02-14 | 2002-09-30 | Warner Lambert Co | TRIAZOLO COMPOUNDS AS MMP INHIBITORS |
| US6962922B2 (en) | 2001-10-12 | 2005-11-08 | Warner-Lambert Company Llc | Alkynylated quinazoline compounds |
| US6894057B2 (en) | 2002-03-08 | 2005-05-17 | Warner-Lambert Company | Oxo-azabicyclic compounds |
| WO2004014892A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Monocyclic derivatives as matrix metalloproteinase inhibitors |
| AU2003249539A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors |
| PA8578101A1 (en) | 2002-08-13 | 2004-05-07 | Warner Lambert Co | HETEROBIARILO DERIVATIVES AS METALOPROTEINASE IN MATRIX INHIBITORS |
| AU2003250470A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Pyrimidinone fused bicyclic metalloproteinase inhibitors |
| EP1553949B1 (en) | 2002-08-13 | 2007-04-18 | Warner-Lambert Company LLC | Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors |
| WO2004014378A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors |
| BR0313724A (en) | 2002-08-13 | 2005-06-28 | Warner Lambert Co | Azaisoquinoline derivatives as matrix metalloproteinase inhibitors |
| MXPA05001785A (en) | 2002-08-13 | 2005-04-25 | Warner Lambert Co | Chromone derivatives as matrix metalloproteinase inhibitors. |
| AU2003253186A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors |
| WO2004014375A2 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Fused bicyclic metalloproteinase inhibitors |
| WO2005016926A1 (en) * | 2003-08-19 | 2005-02-24 | Warner-Lambert Company Llc | Pyrido [3,4-d] pyrimidine derivatives as matrix metalloproteinase-13 inhibitors |
| DE10360835A1 (en) * | 2003-12-23 | 2005-07-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New bicyclic imidazole derivatives are dipeptidylpeptidase-IV inhibitors useful to treat e.g. arthritis, obesity, allograft transplantation and calcitonin-induced osteoporosis |
| BRPI0510305A (en) * | 2004-04-30 | 2007-10-02 | Takeda Pharmaceutical | compound or a salt thereof, prodrug or a salt thereof, pharmaceutical agent, method of producing the compound or a salt thereof, matrix metalloproteinase inhibitor or a salt thereof or a prodrug thereof, method of inhibiting a metalloproteinase matrix, and use of a compound or salt thereof or a prodrug thereof |
| JP2008502666A (en) * | 2004-06-15 | 2008-01-31 | アストラゼネカ アクチボラグ | Substituted quinazolones as anticancer agents |
| CA2665476A1 (en) | 2006-10-05 | 2008-04-10 | Cv Therapeutics, Inc. | Bicyclic nitrogen-containing heterocyclic compounds for use as stearoyl coa desaturase inhibitors |
| AR083475A1 (en) | 2010-10-18 | 2013-02-27 | Merz Pharma Gmbh & Co Kgaa | METABOTROPIC GLUTAMATE RECEIVERS MODULATORS |
| CN103524431B (en) * | 2013-09-24 | 2016-01-13 | 西安交通大学 | 3-benzyl-4-quianzolinones and synthetic method thereof and application |
| JO3512B1 (en) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | Quinoxaline derivatives useful as fgfr kinase modulators |
| HUE057090T2 (en) | 2015-09-23 | 2022-04-28 | Janssen Pharmaceutica Nv | Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer |
| BR112018005637B1 (en) | 2015-09-23 | 2023-11-28 | Janssen Pharmaceutica Nv | COMPOUNDS DERIVED FROM QUINOXALINE, QUINOLINE AND QUINAZOLINONE, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND USE OF SAID COMPOUNDS |
| FR3046793B1 (en) * | 2016-01-14 | 2018-01-05 | Les Laboratoires Servier | NOVEL PHOSPHINAN DERIVATIVES AND AZAPHOSPHINANES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5380398A (en) * | 1996-12-17 | 1998-07-15 | E.I. Du Pont De Nemours And Company | Fungicidal quinazolinones |
| PA8539401A1 (en) * | 2001-02-14 | 2002-10-28 | Warner Lambert Co | QUINAZOLINAS AS INHIBITORS OF MMP-13 |
| PA8539301A1 (en) * | 2001-02-14 | 2002-09-30 | Warner Lambert Co | INHIBITORS OF THE METALOPROTEINASE OF THE MATRIX |
-
2002
- 2002-03-08 WO PCT/EP2002/003240 patent/WO2003076416A1/en not_active Application Discontinuation
- 2002-03-08 AU AU2002249275A patent/AU2002249275A1/en not_active Abandoned
-
2003
- 2003-03-04 SV SV2003001495A patent/SV2003001495A/en not_active Application Discontinuation
- 2003-03-06 JP JP2003574636A patent/JP2005526070A/en not_active Withdrawn
- 2003-03-06 KR KR10-2004-7013994A patent/KR20040095270A/en not_active Application Discontinuation
- 2003-03-06 BR BR0308280-6A patent/BR0308280A/en not_active IP Right Cessation
- 2003-03-06 CA CA002478706A patent/CA2478706A1/en not_active Abandoned
- 2003-03-06 MX MXPA04008681A patent/MXPA04008681A/en unknown
- 2003-03-06 AR ARP030100749A patent/AR039562A1/en not_active Application Discontinuation
- 2003-03-06 AU AU2003212307A patent/AU2003212307A1/en not_active Abandoned
- 2003-03-06 AP APAP/P/2004/003125A patent/AP2004003125A0/en unknown
- 2003-03-06 OA OA1200400234A patent/OA12782A/en unknown
- 2003-03-06 PA PA20038568501A patent/PA8568501A1/en unknown
- 2003-03-06 IL IL16381803A patent/IL163818A0/en unknown
- 2003-03-06 CN CNA038048752A patent/CN1738806A/en active Pending
- 2003-03-06 WO PCT/EP2003/002277 patent/WO2003076417A2/en not_active Application Discontinuation
- 2003-03-06 PE PE2003000218A patent/PE20031018A1/en not_active Application Discontinuation
- 2003-03-06 UY UY27700A patent/UY27700A1/en not_active Application Discontinuation
- 2003-03-06 EA EA200401053A patent/EA200401053A1/en unknown
- 2003-03-06 EP EP03708181A patent/EP1492775A2/en not_active Withdrawn
- 2003-03-06 PL PL03372622A patent/PL372622A1/en not_active Application Discontinuation
-
2004
- 2004-08-19 IS IS7414A patent/IS7414A/en unknown
- 2004-08-25 CO CO04082792A patent/CO5601020A2/en not_active Application Discontinuation
- 2004-08-31 MA MA27842A patent/MA27183A1/en unknown
- 2004-09-03 EC EC2004005278A patent/ECSP045278A/en unknown
- 2004-09-03 TN TNP2004000169A patent/TNSN04169A1/en unknown
- 2004-09-24 NO NO20044041A patent/NO20044041L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CO5601020A2 (en) | 2006-01-31 |
| AU2002249275A1 (en) | 2003-09-22 |
| WO2003076417A2 (en) | 2003-09-18 |
| CA2478706A1 (en) | 2003-09-18 |
| WO2003076417A3 (en) | 2003-11-13 |
| PL372622A1 (en) | 2005-07-25 |
| MXPA04008681A (en) | 2004-12-06 |
| JP2005526070A (en) | 2005-09-02 |
| IL163818A0 (en) | 2005-12-18 |
| TNSN04169A1 (en) | 2007-03-12 |
| AR039562A1 (en) | 2005-02-23 |
| EA200401053A1 (en) | 2005-04-28 |
| SV2003001495A (en) | 2003-11-04 |
| OA12782A (en) | 2006-07-10 |
| MA27183A1 (en) | 2005-01-03 |
| PE20031018A1 (en) | 2004-01-09 |
| EP1492775A2 (en) | 2005-01-05 |
| NO20044041L (en) | 2004-10-07 |
| AP2004003125A0 (en) | 2004-09-30 |
| AU2003212307A1 (en) | 2003-09-22 |
| WO2003076416A1 (en) | 2003-09-18 |
| UY27700A1 (en) | 2003-10-31 |
| PA8568501A1 (en) | 2003-12-19 |
| IS7414A (en) | 2004-08-19 |
| ECSP045278A (en) | 2004-10-26 |
| CN1738806A (en) | 2006-02-22 |
| KR20040095270A (en) | 2004-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0308280A (en) | Oxo-azabicyclic compounds | |
| BRPI0512659A (en) | chemical compounds | |
| BRPI0212726B8 (en) | compounds containing lactams, and derivatives thereof, pharmaceutical composition comprising them and their uses | |
| BR0206433A (en) | Compound, pharmaceutical composition, process for preparing a compound, and use of a compound | |
| BRPI0110955B8 (en) | tropane derivatives pharmaceutical composition, their use in the manufacture of a drug as well as a process for their preparation. | |
| BRPI0008753B8 (en) | amide compound, process for preparing an amide compound, pharmaceutical composition and use of an amide compound | |
| BR9914451A (en) | Oxazole compound, process for its preparation, pharmaceutical composition comprising said compound, use of the composition and treatment methods | |
| BR0212378A (en) | 17betahydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
| BR0310077A (en) | New compounds and their use | |
| BR0213239A (en) | Alkynylated condensed ring pyrimidine compounds as type 13 matrix metalloproteinase inhibitors | |
| BRPI0408353A (en) | compound, pharmaceutical composition, methods for the treatment of susceptible neoplasms and for the treatment of viral infections, and, use of a compound | |
| BR0308765A (en) | (4,2-Disubstituted-thiazol-5-yl) amine compounds as pde7 inhibitors | |
| BR0212069A (en) | Oral antidiabetic agents | |
| BR0003848A (en) | Pyridine compounds, process for their preparation and pharmaceutical compositions containing them | |
| ATE279411T1 (en) | FLUORescent markers | |
| BRPI0602132A (en) | indanyl piperazine compounds, processes for their preparation and pharmaceutical compositions containing them | |
| BR0309558A (en) | Quinazoline derivatives and medicines | |
| BR0311410A (en) | Piperidine Compound | |
| BR9916669A (en) | Use of derivatives of substituted 4-biarylbutyric and 5-biarylpentanoic acids as matrix metalloprotease inhibitors for the treatment of respiratory diseases | |
| BR0104471A (en) | Cyclobutenodione compounds, a process for their preparation and pharmaceutical compositions containing the same | |
| BR0214937A (en) | Process of preparation of echinocandin derivatives | |
| BRPI0411308A (en) | compound, pharmaceutical composition, process for preparing a compound, and use of a compound | |
| ES2183492T3 (en) | NEW NITRON DERIVATIVES, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
| BR0211903A (en) | Isoxazolopyridinones | |
| BR0207795A (en) | Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as ip antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 4A, 5A, 6A E 7A ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2051 DE 27/04/2010. |